Lactea Therapeutics, LLC
Lactea Therapeutics, founded in 2021 in Frederick, MD, is dedicated to advancing naturally occurring, safe, broad-spectrum active molecules as a new class of antibiotic alternatives. Their mission is to reduce the risk of resistance, limit disruption of the microbiome, and decrease the transmission of harmful microbes by harnessing the power of innate immune system proteins. The company leverages patent-pending technology to develop products based on endemic proteins that have evolved to provide broad protection against infections, aiming to translate these natural defenses into pharmaceutical solutions.
Industries
N/A
Nr. of Employees
small (1-50)
Lactea Therapeutics, LLC
Lactea Therapeutics, LLC is currently seeking investment
Lactea Therapeutics, LLC is seeking a series-b investment in the range of 1m-5m
Products
Topical oral biofilm barrier for field dental care
A topical formulation intended to act as a barrier against oral biofilms in austere or field settings where routine hygiene is limited.
Isolated innate immune peroxidase enzyme candidate
An isolated peroxidase‑class innate immune protein with demonstrated antioxidant activity for potential therapeutic or countermeasure applications.
Topical oral biofilm barrier for field dental care
A topical formulation intended to act as a barrier against oral biofilms in austere or field settings where routine hygiene is limited.
Isolated innate immune peroxidase enzyme candidate
An isolated peroxidase‑class innate immune protein with demonstrated antioxidant activity for potential therapeutic or countermeasure applications.
Expertise Areas
- Innate immune protein therapeutics
- Antimicrobial alternatives development
- Ambient‑stable biologic formulation
- Field‑deployable medical countermeasures
Key Technologies
- Protein isolation and purification
- Enzyme activity and antioxidant assays (peroxidase characterization)
- Ambient‑stable formulation technologies for biologics
- Topical barrier formulation for biofilm control
Key People
Christopher Hlubb
CEO
Christopher Hlubb
CEO
News & Updates
Lactea Therapeutics has developed patent-pending technology to utilize endemic proteins evolved for broad protection, aiming to create new pharmaceutical solutions for infection prevention.
Lactea Therapeutics has developed patent-pending technology to utilize endemic proteins evolved for broad protection, aiming to create new pharmaceutical solutions for infection prevention.